TUCSON, Ariz., August 8, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today a new research grant awarded to Daniela C. Zarnescu, Ph.D., Professor of Cellular and Molecular Physiology at Penn State University College of Medicine, in collaboration with Jon Njardarson, Ph.D., Professor at the University of Arizona. Continue reading
Category Archives: AZBio News
C-Path Inaugural Global Impact Conference: Pioneering Drug Development Collaborations
Sept. 9-11, 2024, Washington, D.C.Continue reading
C-Path Welcomes New Advisory Members to Alpha-1 Antitrypsin Deficiency Consortium
TUCSON, Ariz., August 6, 2024 — Critical Path Institute’s (C-Path) Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortium today announced the addition of several key advisory members. Continue reading
Anivive Receives NIAID Contract Worth Up to $33M to Progress Valley Fever Vaccine
LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ – Anivive Lifesciences Inc, a One Health technology company today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded Anivive a new contract (#75N93024C00009) worth up to $33M to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.Continue reading
AZMN Founders to Receive the 2024 AZBio Service Award
Jack and Barbara Kavanagh, founders of the Arizona Myeloma Network and Cancer Caregivers of America, will be honored with the AZBio Service Award at the 20th annual AZBio Awards on September 18, 2024 at the Phoenix Convention Center.Continue reading
Valley Fever: Stakeholders Explore Developing Vaccines for Fungal Diseases
The FDA, NIH, and CDC will bring together a diverse group of stakeholders to summarize progress toward developing vaccines against fungal diseases, with an emphasis on our current understanding of the epidemiology, biology, and immunology of Valley feverContinue reading
ACA Supercharges Support For Arizona Startups
- New venture programs launched to scale Arizona Innovation Challenge
- Applications for the next round of the Arizona Innovation Challenge opened August 1, 2024 and close August 30, 2024.
Protein Homeostasis May Hold the Key to More Successful Treatment of Heart Disease
Coronary artery disease (CAD) is the most common form of heart disease, the leading cause of death for both men and women. Of the roughly 695,000 people who died from heart disease in 2021, more than 375,000 deaths were attributable to CAD, according to the Centers for Disease Control and Prevention (CDC).Continue reading
James Goulka named President & CEO of Arizona Venture Development Corp (AVC)
As President & CEO, James “Jim” Goulka leads AVC’s initiatives to invest in early-stage technology startups and funds across enterprise, software, consumer, climate-tech, and bio/health tech—all while helping catalyze access to equity capital for underserved founders and communities in Arizona.Continue reading
University of Arizona had record number of inventions in FY24
Tech Launch Arizona, the University of Arizona office that commercializes inventions stemming from university research and innovation, saw a record number of inventions during the 2024 fiscal year.
Between July 1, 2023, and June 30, 2024, TLA received 307 new inventions, up from 298 in fiscal year 2023 and 303 in fiscal year 2022. The office also launched nine startups; executed 72 licenses and options for U of A inventions; filed 367 patents; and had 78 patents issued